Abstract

O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification involving an attachment of a single β-N-acetylglucosamine moiety to serine or threonine residues in nuclear and cytoplasmic proteins. Cellular O-GlcNAc levels are regulated by two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), which add and remove the modification, respectively. The levels of O-GlcNAc can rapidly change in response to fluctuations in the extracellular environment; however, O-GlcNAcylation returns to a baseline level quickly after stimulus removal. This process termed O-GlcNAc homeostasis appears to be critical to the regulation of many cellular functions including cell cycle progress, stress response, and gene transcription. Disruptions in O-GlcNAc homeostasis are proposed to lead to the development of diseases, such as cancer, diabetes, and Alzheimer’s disease. O-GlcNAc homeostasis is correlated with the expression of OGT and OGA. We reason that alterations in O-GlcNAc levels affect OGA and OGT transcription. We treated several human cell lines with Thiamet-G (TMG, an OGA inhibitor) to increase overall O-GlcNAc levels resulting in decreased OGT protein expression and increased OGA protein expression. OGT transcript levels slightly declined with TMG treatment, but OGA transcript levels were significantly increased. Pretreating cells with protein translation inhibitor cycloheximide did not stabilize OGT or OGA protein expression in the presence of TMG; nor did TMG stabilize OGT and OGA mRNA levels when cells were treated with RNA transcription inhibitor actinomycin D. Finally, we performed RNA Polymerase II chromatin immunoprecipitation at the OGA promoter and found that RNA Pol II occupancy at the transcription start site was lower after prolonged TMG treatment. Together, these data suggest that OGA transcription was sensitive to changes in O-GlcNAc homeostasis and was potentially regulated by O-GlcNAc.

Highlights

  • O-linked N -acetylglucosamine (O-GlcNAc) is a posttranslational modification (PTM) first discovered by Gerald W

  • Cells overexpressing O-GlcNAc transferase (OGT) showed an elevation in O-GlcNAc levels and a slight increase in OGA protein expression compared to control, while cells overexpressing OGA showed a decrease in O-GlcNAc levels and a slight increase in OGT protein expression compared to control (Figure 1D)

  • Prolonged alterations in homeostatic levels of O-GlcNAc will cause the protein expression of OGT and OGA to change in an effort to restore O-GlcNAc homeostasis [4]

Read more

Summary

Introduction

O-linked N -acetylglucosamine (O-GlcNAc) is a posttranslational modification (PTM) first discovered by Gerald W. Hart and Carmen-Rosa Torres in 1984 [1]. They initially used bovine milk galactosyltransferase (GalT1) to probe for terminal N-acetylglucosamine glycoconjugates on T-cells and unexpectedly discovered the existence of single β-N -acetylglucosamine conjugated proteins inside the cell [1]. O-GlcNAc is a reversible modification that is ubiquitiously expressed in higher eukaryotes. O-GlcNAc transferase (OGT) is the enzyme that adds the OGlcNAc modification, whereas O-GlcNAcase (OGA) removes it [2, 3]. Because uridine diphosphate-N-acetyl-glucosamine (UDPGlcNAc), the end point of the hexosamine biosynthetic pathway, is the high-energy donor substrate for OGT, O-GlcNAcylation is sensitive to nutrient availability [4]. Nutrients, or the environment cause within minutes to several hours changes to the total level of

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call